Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1998-8-25
|
| pubmed:abstractText |
Non-Hodgkin's lymphomas (NHL) are B-cell malignancies which generally present molecular abnormalities, such as bcl-2 translocation t(14; 18) predominantly in the follicular subgroup. Other molecular events have been described in NHL, including p53 gene mutation and overexpression of one chemoresistance mechanism, the multidrug resistance system, P-glycoprotein (MDR 1/P-gp). In this study, we analysed samples from 44 NHL patients with the presence of the bcl-2 major breakpoint region (MBR) rearrangement in 29 and without in 15. Immunochemical analysis revealed that 39 samples were positive for bcl-2 protein expression in tumoral cells (88.6%). Seventeen (38.6%) patients expressed P-gp and 9 (20.5%) expressed p53 proteins. Eleven patients expressed both bcl-2 and P-gp proteins, four expressed bcl-2 and p53 proteins whereas four expressed bcl-2, p53 and P-gp proteins. Our results confirm the importance of p53 expression as a key prognostic factor, and no objective response (OR) was found in patients with p53 positivity. MBR rearrangement was not associated with poor response to chemotherapy (62.1% OR in MBR positive patients v. 60% OR in MBR negative patients). The clinical impact of P-gp cannot be identified because no relationship was observed between P-gp expression and prognosis (58.8% OR in P-gp positive patients v. 63% OR in P-gp negative patients).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0141-9854
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
87-94
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9681218-Adult,
pubmed-meshheading:9681218-Aged,
pubmed-meshheading:9681218-Aged, 80 and over,
pubmed-meshheading:9681218-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9681218-Chromosomes, Human, Pair 14,
pubmed-meshheading:9681218-Chromosomes, Human, Pair 18,
pubmed-meshheading:9681218-DNA, Neoplasm,
pubmed-meshheading:9681218-DNA Mutational Analysis,
pubmed-meshheading:9681218-Disease Progression,
pubmed-meshheading:9681218-Drug Resistance, Multiple,
pubmed-meshheading:9681218-Drug Resistance, Neoplasm,
pubmed-meshheading:9681218-Female,
pubmed-meshheading:9681218-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:9681218-Genes, bcl-2,
pubmed-meshheading:9681218-Genes, p53,
pubmed-meshheading:9681218-Humans,
pubmed-meshheading:9681218-Lymphoma, Non-Hodgkin,
pubmed-meshheading:9681218-Male,
pubmed-meshheading:9681218-Middle Aged,
pubmed-meshheading:9681218-Neoplasm Proteins,
pubmed-meshheading:9681218-P-Glycoprotein,
pubmed-meshheading:9681218-Polymerase Chain Reaction,
pubmed-meshheading:9681218-Prognosis,
pubmed-meshheading:9681218-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:9681218-Translocation, Genetic,
pubmed-meshheading:9681218-Treatment Outcome,
pubmed-meshheading:9681218-Tumor Cells, Cultured
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
MBR rearrangement and P-glycoprotein expression are not independent prognostic factors like p53 protein in malignant lymphoma.
|
| pubmed:affiliation |
INSERM, Montpellier, France.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|